March 2, 2020 / 1:57 PM / a month ago

BRIEF-U.S. FDA Accepts Regulatory Submission For Tanezumab

March 2 (Reuters) - Eli Lilly and Co:

* U.S. FDA ACCEPTS REGULATORY SUBMISSION FOR TANEZUMAB, A POTENTIAL FIRST-IN-CLASS TREATMENT FOR PATIENTS WITH CHRONIC PAIN DUE TO MODERATE-TO-SEVERE OSTEOARTHRITIS

* PFIZER INC - PDUFA GOAL DATE FOR FDA TO MAKE A DECISION ON TANEZUMAB APPLICATION IS IN DECEMBER 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below